$NTRA News

$100 Invested In Natera 10 Years Ago Would Be Worth This Much Today

Wolfe Research Assumes Natera at Outperform, Announces Price Target of $260

Natera Announces Enrollment Of First Patients In SIGNAL-ER 101, A Prospective Study Evaluating Signatera MRD-Guided De-Escalation In Early-Stage Breast Cancer

Natera: A Growing Biotech, After Recent FDA Approval And Q1 Revenue Results

Natera Enhances Its Panorama Non-Invasive Prenatal Test, Adding Clinically-Validated Performance Data

If You Invested $1000 In Natera Stock 10 Years Ago, You Would Have This Much Today

Natera Expands North Austin HQ With New Sequencing Facility And Added Space, Boosting Capacity Amid 54% Oncology Volume Growth

Natera Announces That Its EXPAND Clinical Trial Has Enrolled Over 2,000 Patients, More Than Doubling Enrollment In The Last 12 Months

Natera Receives FDA Approval For Signatera CDx As Companion Diagnostic For Use With Adjuvant Atezolizumab Immunotherapy In Muscle-Invasive Bladder Cancer

BTIG Maintains Buy on Natera, Lowers Price Target to $250

JP Morgan Maintains Overweight on Natera, Raises Price Target to $265

Evercore ISI Group Maintains Outperform on Natera, Raises Price Target to $270

Wells Fargo Maintains Equal-Weight on Natera, Raises Price Target to $220

Natera (NTRA) Q1 Revenue Beat Overshadowed by EPS Miss and Operating Losses

Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript

Natera, Inc. 2026 Q1 - Results - Earnings Call Presentation

Natera Raises FY2026 Sales Guidance from $2.620B-$2.700B to $2.740B-$2.820B vs $2.668B Est

Natera Q1 EPS $(0.60) Misses $(0.57) Estimate, Sales $696.644M Beat $617.110M Estimate

Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst

William Blair Initiates Coverage On Natera with Outperform Rating